Back

Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: a systematic review and network meta-analysis

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Epidemiology and artificial intelligence Coronary Arteries ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Mattia Galli

Sapienza University of Rome, Rome (Italy)

7 More presentations in this session

Presentation thumbnail
Outcomes comparison between robotic and conventional mitral valve surgery: a systematic review and meta-analysis
Ms J. Pratita (Central Jakarta, ID)
Abstract Slides
Presentation thumbnail
Impact of surgical left atrial appendage closure during coronary bypass on clinical outcomes and readmissions
Doctor L. Wu (Greenville, US)
Abstract Slides
Presentation thumbnail
Artificial intelligence as a precision tool for predicting risk of in-hospital death after aortic valve replacement
Doctor A. Rosler (Porto Alegre, BR)
Abstract Slides
Presentation thumbnail
Large multinational evaluation of time to reintervention in patients undergoing bioprosthetic valve implantation during open heart surgery
Doctor T. Maller (Jerusalem, IL)
Abstract Slides
Presentation thumbnail
Artificial intelligence as a precision tool for predicting risk of in-hospital death after coronary artery bypass graft surgery
Doctor A. Rosler (Porto Alegre, BR)
Abstract Slides

Access the full session

Session thumbnail
Epidemiology and artificial intelligence

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Anomalous left main coronary artery arising from the right coronary sinus presenting with ST elevation and non ST elevation myocardial infarction
thumbnail
Congress Presentation
Surgical correction of anomalous origin of the coronary artery: a scoping review on clinical outcomes, techniques, and knowledge gaps
thumbnail
Webinar
Chronic coronary syndrome post-myocardial infarction: disease progression and comorbidities

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources